Pioglitazone (PIO), a PPAγ agonist that improves glycemic control in T2DM through its insulin-sensitizing action, was shown to inhibit vascular smooth muscle cell proliferation, and the inhibitory effect was mediated by AMPK activation and/or diminishing of PDGF-induced mechanistic target of rapamycin (mTOR) activity [81]. Here, PRKAA2 is linked to type 2 diabetes mellitus.